Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
60 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ixX pharma from Antwerpen, company number BE0873490740, closed financial year 2025 with a result of € 1.7 million after tax. For that financial year ixX pharma recorded revenue of € 11.6 million and equity of € 6.9 million. Compared with financial year 2024, the result moved from € 1.2 million to € 1.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 6.9 million
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.7 million
▲ 40% vs 2024
Profit after tax over the fiscal year.
€ 1.3 million
▲ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.1 million paid out
62 % of the profit went to the shareholders, mostly to Ponroy Vitarmonyl Benelux BV (100 % of the shares). That is where the money ends up.
People and assets in 2025
26.3
▼ 1.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.5 million
▼ 2% vs 2024
€ 95,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 1 million
Loans from banks and other lenders, long and short.
€ 1.1 million
▼ 51% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 52 days on average.
€ 997,907
▲ 33% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 9,726,325 | € 10,436,315 | € 12,768,776 | € 11,631,876 | ▼ 9% |
| Profit after taxes | € 392,379 | € 1,010,190 | € 1,206,625 | € 1,692,646 | ▲ 40% |
| Equity | € 4,829,163 | € 5,076,852 | € 6,283,477 | € 6,926,124 | ▲ 10% |
| Total debts | € 2,567,604 | € 3,665,874 | € 4,010,450 | € 4,347,912 | ▲ 8% |
| Cash | € 838,793 | € 1,072,640 | € 1,313,062 | € 1,347,465 | ▲ 3% |
| Land & buildings | € 635,463 | € 574,926 | € 514,714 | - | |
| Retained profit | € 4,316,714 | € 4,476,904 | € 5,683,528 | € 6,326,175 | ▲ 11% |
| Dividend | € 1,000,000 | € 850,000 | € 0 | € 1,050,000 | |
| Bank debt | € 1,000,000 | € 1,000,000 | € 1,000,000 | € 1,000,000 | |
| Balance sheet total | € 7,396,767 | € 8,742,726 | € 10,293,927 | € 11,274,036 | ▲ 10% |
| Employees (FTE) | 19 | 21.8 | 27.4 | 26.3 | ▼ 1.1 |
Key figures of ixX pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ixX pharma?
What happened at ixX pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.7 million (▲ 40% vs 2024). filed late Source: NBB ↗
- Ponroy Vitarmonyl Benelux BV stepped down as director. NBB
- Matthieu Mourette stepped down as director. NBB
- Ponroy Vitarmonyl Benelux BV became a director. NBB
- Matthieu Mourette became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 392,379 profit in 2022 to € 1.7 million profit in 2025.
Paid € 1.6 million in corporate taxes since 2022.
Best year ever: 2025, with € 1.7 million profit.
Paid out € 2.9 million in dividends to the owners in total.
A new publication or filing at ixX pharma? We notify you, reason included.
Follow ixX pharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Ponroy Vitarmonyl Benelux BV (100%). It owns 100% of Biocyte Benelux itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Nicolas Brodetsky
since 2021 · until 2026
Matthieu Mourette
Director
since 2021 · until 2026
Shareholders
Participations
100%
Establishments
Establishment units
Physical locations of this company
Borsbeeksebrug 34
2600 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 60 companies are registered at this address.
All companies at this address →Athena
PIZZA BELGIUM
€ 45.8 million revenue · 2025
MABEMI
€ -5,762 gross margin · 2022
C & C LASER
€ -50,670 gross margin · 2025
Linde Gas Belgium
€ 13.1 million revenue · 2025
+55 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
Website info
Features
Security
Network
Details
- Company number
- 0873.490.740
- VAT number
- BE 0873.490.740
- Registered office
- Borsbeeksebrug 34, 2600 Antwerpen
- Names & denominations
- ixX pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 April 2005
- Peppol
- Active · Active since 30 Jul 2025
- Contact
- ixx.be
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen